Trial · NCT02317627
Outcomes22
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population | 12 weeks | Intent-to-Treat (ITT) Population: All subjects enrolled in study | Percentage of participants (%) | NUMBER |
| PRIMARY | Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population | 12 weeks | Evaluable Population: Subjects who receive at least 80% of the expected amount of study drug if the subject had completed the study | Percentage of participants (%) | NUMBER |
| PRIMARY | Safety: Percentage of Subjects With AEs by Severity and Relationship to Belumosudil--ITT Population | 12 weeks | ITT Population: All enrolled subjects | Percentage of participants (%) | NUMBER |
| SECONDARY | Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--ITT Population | 12 weeks | Intent-to-Treat (ITT) Population: All enrolled subjects | Score on a scale | MEAN |
| SECONDARY | Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--Evaluable Population | 12 weeks | Intent-to-Treat (ITT) Population: All enrolled subjects | Score on a scale | MEAN |
| SECONDARY | Efficacy: Percentage of Subjects With a Decrease in PASI After 4 Weeks---ITT Population | 4 weeks | Intent-to-Treat (ITT) Population: All enrolled subjects | Percentage of participants (%) | NUMBER |
| SECONDARY | Efficacy: Percentage of Subjects With a Decrease in PASI Score After 8 Weeks---ITT Population | 8 weeks | Intent-to-Treat (ITT) Population: All enrolled subjects | Percentage of participants (%) | NUMBER |
| SECONDARY | Efficacy: Percentage of Subjects With a Decrease in PASI Score at EOT---ITT Population | 12 weeks | Intent-to-Treat (ITT) Population: All enrolled subjects | Percentage of participants (%) | NUMBER |
| SECONDARY | Efficacy: Percentage of Subjects With a Decrease in PASI Score After 4 Weeks, 8 Weeks, and 12 Weeks---Evaluable Population | 12 weeks | Evaluable Population: Subjects who received at least 80% of the expected amount study drug if the subject had completed the study | Percentage of participants (%) | NUMBER |
| SECONDARY | Efficacy: Mean Change in PASI Score After 4 Weeks---ITT Population | 4 weeks | Intent-to-Treat (ITT) Population: All enrolled subjects | Score on a scale | NUMBER |
| SECONDARY | Efficacy: Mean Change in PASI Score After 8 Weeks---ITT Population | 8 weeks | Intent-to-Treat (ITT) Population: All enrolled subjects | Score on a scale | NUMBER |
| SECONDARY | Efficacy: Mean Change in PASI Score at 4 and 8 Weeks---Evaluable Population | 8 weeks | Evaluable Population: Subjects who received at least 80% of the expected amount of study drug if the subject had completed the study | Score on a scale | NUMBER |
| SECONDARY | Efficacy: Percentage of Subjects With Improvement in PGA af 4 Weeks---ITT Population | 4 weeks | Intent-to-Treat (ITT) Population: All enrolled subjects | Percentage of participants | NUMBER |
| SECONDARY | Efficacy: Percentage of Subjects With Improvement in PGA af 8 Weeks---ITT Population | 8 weeks | Intent-to-Treat (ITT) Population: All enrolled subjects | Percentage of participants | NUMBER |
| SECONDARY | Efficacy: Percentage of Subjects With Improvement in PGA af EOT--ITT Population | 12 weeks | Intent-to-Treat (ITT) Population: All enrolled subjects | Percentage of participants | NUMBER |
| SECONDARY | Efficacy: Percentage of Subjects With Improvement in PGA af 4, 8, and 12 Weeks---Evaluable Population | 12 weeks | Evaluable Population: Subjects who received at least 80% of the expected amount of study drug if the subject had completed the study | Percentage of participants | NUMBER |
| SECONDARY | Efficacy: Mean Changes in DLQI at EOT--ITT Population | 12 weeks | Intent-to-Treat: All enrolled subjects. | Score on a scale | MEAN |
| SECONDARY | Efficacy: Mean Changes in DLQI at 12 Weeks--Evaluable Population | 12 weeks | Evaluable Population: Subjects who received at least 80% of the expected amount of study drug if the subject had completed the study | Score on a scale | MEAN |
| SECONDARY | Pharmacokinetics: Cmax of Parent Drug KD025, KD025m1, and KD025m2 | 24 hours | PK Population: Subjects received at least 1 dose of study drug and had at least 1 post-dose PK sample drawn.~Note: Not all subjects had all data available for PK parameters. | ng/mL | MEAN |
| SECONDARY | Pharmacokinetics: AUC of Parent Drug KD025, KD025m1, and KD025m2 | 24 hours | PK Population: Subjects received at least 1 dose of study drug and had at least 1 post-dose PK sample drawn.~Note: KD025m2 did not have AUC(0-12) or AUC(0-24) available. Not all subjects had all PK measurements. AUC(0-12) and AUC(0-24) for KD025m1 were not calculable. | hour*ng/mL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02317627/outcomes